{"authors": ["Katie Thomas"], "date_download": "2022-10-25 23:23:30", "date_modify": "2022-10-25 23:23:30", "date_publish": "2012-10-11 04:01:45", "description": "The drug company GlaxoSmithKline hopes that making its research available to scientists will lead to safer, more effective drugs.", "filename": "2012_10_11_business_glaxo-opens-door-to-data-on-its-research_1666740210.html", "image_url": "https://static01.nyt.com/newsgraphics/images/icons/defaultPromoCrop.png?year=2012", "language": "en", "localpath": "/Users/matthewwhite/news-please-repo//data/2022/10/25/nytimes.com/2012_10_11_business_glaxo-opens-door-to-data-on-its-research_1666740210.html", "title": "Glaxo Opens Door to Data on Its Research", "title_page": "Glaxo Opens Door to Data on Its Research - The New York Times", "title_rss": "NULL", "source_domain": "nytimes.com", "maintext": "GlaxoSmithKline plans to open up much of its drug research in an apparent effort to deflect criticism that important information gathered in clinical trials often does not see the light of day.\nThe move, a first for a major pharmaceutical company, is scheduled to be announced on Thursday by its chief executive, Andrew Witty, in London.\nResearchers contacted about the plan on Wednesday expressed a mix of enthusiasm and skepticism, citing the recent $3 billion settlement by GlaxoSmithKline with the federal government over charges that the company had misrepresented trial data for popular drugs like Avandia and Paxil.\nStill, the company is taking a step in the right direction, the researchers said, and might set a precedent in an industry that could use more transparency.", "url": "https://www.nytimes.com/2012/10/11/business/glaxo-opens-door-to-data-on-its-research.html"}